Merck (MRK) Announces European Commission Approves KEYTRUDA Plus LENVIMA for Patients With Certain Types of Endometrial Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. NVDA
7. BLZE
8. IBM
9. PRIM
10. ACN

Go back to Merck (MRK) Announces European Commission Approves KEYTRUDA Plus LENVIMA for Patients With Certain Types of Endometrial Carcinoma
Merck & Co. (NYSE: MRK) Delayed: 119.62 +4.14 (3.59%)
Previous Close $115.48    52 Week High $65.46 
Open $116.53    52 Week Low $47.97 
Day High $119.80    P/E 81.37 
Day Low $116.53    EPS $1.47 
Volume 7,037,822